SJ

Shubhra Jain

Physician turned Investor passionate about cutting edge technologies in health and bio!

San Francisco, California

Overview 

Shubhra Jain is a former physician turned Investor based in San Francisco, California, currently serving as the Head of Healthcare Investments at Tarsadia Investments. With a diverse background in medical devices and bioengineering, Shubhra has successfully invested in companies like Berkeley Lights (Series E) and Mission Bio (Series B), showcasing a strong track record in supporting cutting-edge technologies in health and bio. Having transitioned from a medical career to a prominent role in the investment sector, Shubhra Jain has leveraged her expertise to lead cross-functional teams and drive successful business strategies, positioning herself as a key player in the venture capital landscape for innovative startups in sectors such as Medical Devices and BioTech.

Work Experience 

  • Head of Healthcare Investments

    2022 - Current

    Lead venture and growth investments in health and bio Select portfolio - Fathom - Phil - Cue - Chronus

Tarsadia Investments is a private investment firm that provides capital and strategic support.

  • Managing Partner

    2020

  • Investor

    2018

Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.

Raised $337,567,756.00 from Varian, Paxion Capital Partners, Walden Riverwood Ventures, Nikon, KTB Network, Black Diamond Ventures, Shangbay Capital, Atinum Partners, AJS Investments and Cota Capital.

  • Investor

    2018

Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.

Raised $974,140,000.00 from SoftBank Vision Fund, DCVC, True Ventures, Baron Capital, Perceptive Advisors, Baillie Gifford and Employee Stock Option Fund.

  • Digital Health Council

    2018

    Advisor and mentor to digital health startups in the Springboard portfolio. Lending my time and network to help support and empower a new set of exciting women-led companies every year.

Springboard’s mission is to accelerate the growth of entrepreneurial companies led by women.

  • Global Mentor

    2018

    Endeavor is the only non-profit that supports high-impact entrepreneurs around the world. Our "mentor capitalist"​ model breaks down economic and cultural barriers to entrepreneurship through advising from our network of world-class business leaders. With their guidance, our 1600+ Endeavor Entrepreneurs throughout Latin America, Africa, the Middle East, Southeast Asia and the U.S. have created 1.5 million high-value jobs and, generate $15 billion in revenues each year, and inspire future generations of entrepreneurs to innovate and take risks.

Endeavor supports high-impact entrepreneurs around the world. Endeavor Catalyst is the rules-based, co-investment fund of Endeavor.

Raised $130,000,000.00 from Nour Nouf.

  • Board Member

    2018

    FemTech Collective is the premiere network connecting innovators in the female focused health technology space through unique and impactful events.

A growing collective of over 200 FemTech startups, established companies, investors, and industry professionals.

  • Principal

    2018 - 2020

    Cota takes a unique and differentiated approach to investing by identifying attractive investments across private and public markets, from early-stage venture to public companies. This thematic, stage agnostic, and operationally engaged approach provides flexibility to deploy funding at the most opportunistic points within the innovation and liquidity cycles. Cota Capital is led by a strong team of investors, entrepreneurs, and company-builders, and partners with world-class entrepreneurs and leadership teams to build businesses that leverage technology in innovative ways to disrupt all industries.

Cota Capital is a technology investment firm that partners with exceptional teams to build and grow timeless companies.

  • Board

    2018 - 2020

    Mission Bio’s Tapestri® Platform provides unprecedented insight into the heterogeneity among cells that drive complex diseases like cancer, so you can map disease progression and better guide dynamic treatment.

Mission Bio develops only single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development.

Raised $150,898,729.00 from Novo Holdings, Cota Capital, Soleus Capital, Mayfield Fund, Seabed VC and Agilent Ventures.

  • Board

    2018 - 2020

    Bioniz leverages its world-class expertise in cytokine biology, originating in research conducted at the National Institutes of Health (NIH), to develop a novel approach to selectively inhibit functionally redundant cytokines by blocking their unique binding interface with their shared receptor. Through our platform, we have identified a number of product candidates that address immuno-inflammatory diseases and cancer.

Articles About Shubhra

Relevant Websites